2227017-46-9
2227017-46-9
Chemical Structure
RS5517
- CAS No.: 2227017-46-9
- Formula:C23H19ClN2O2
- Molecular Weight:390.86
InChIKey: FHIRYPMBXVLHTD-UHFFFAOYSA-N
SMILES: O=C(C1=C(CC2=CC=CC=C2)C3=C(C=CC(Cl)=C3)N1)NC4=CC=C(CO)C=C4
Biological Activity: RS5517 is a specific PDZ1-domain antagonist of NHERF1 that prevented its ectopic nuclear entry. RS5517 can be used for the research of colorectal cancer[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
RS5517 | 95.79% | RS5517 is a specific PDZ1-domain antagonist of NHERF1 that prevented its ectopic nuclear entry. RS5517 can be used for the research of colorectal cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Saponaro C, et al. β-catenin knockdown promotes NHERF1-mediated survival of colorectal cancer cells: implications for a double-targeted therapy. Oncogene. 2018 Jun;37(24):3301-3316. doi: 10.1038/s41388-018-0170-y. Epub 2018 Mar 19. [Content Brief]
- [2]. Capdevielle C, et al. HDAC inhibition induces expression of scaffolding proteins critical for tumor progression in pediatric glioma: focus on EBP50 and IRSp53. Neuro Oncol. 2020 Apr 15;22(4):550-562. [Content Brief]
